Bucillamine clinical trials
How each study uses bucillamine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Bucillamine
- 4
Studies by the year they started
4 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Revive Therapeutics, Ltd. (3) · Saitama Medical University (1)
Related medicines
As reviewed, each with the page that says it.
- One of Anti-Inflammatory Agents, Non-Steroidal source
- One of Antioxidants source
Studies
Open first, then newest update. How each study uses bucillamine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Bucillamine in Treatment of Patients With COVID-19TerminatedPhase 3Revive Therapeutics, Ltd.NCT04504734Written as Bucillamine
- Bucillamine Phase 2 Trial in Patients With CystinuriaStatus unknownPhase 2Revive Therapeutics, Ltd.NCT02942420Written as Bucillamine
- Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe GoutCompletedPhase 2Revive Therapeutics, Ltd.NCT02330796Written as Bucillamine
- Bucillamine Study of Holding Remission After Infliximab Dose-offStatus unknownPhase 4Saitama Medical UniversityNCT00716248Written as bucillamine
Given beside what is tested · 1 — bucillamine is usual care or a partner of the new treatment
Codes
What other systems call bucillamine · ClinicalTrials.gg INT002839
- MeSH (NLM) C026535bucillamineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) R80LRA5WTFBUCILLAMINEConfirmed FDA, NLM, Wikidata
- Wikidata Q4982752BucillamineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C83561BucillamineOne source FDA
- DrugBank DB12160One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C026535 | bucillamine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | R80LRA5WTF | BUCILLAMINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4982752 | Bucillamine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C83561 | Bucillamine | One source FDA |
| DrugBank | DB12160 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.